摘要
Intrahepatic cholangiocarcinoma(ICC),a rare but rising global malignancy originating from the bile ducts,poses significant challenges in terms of effective treatment and patient outcomes.While surgical excision remains the curative option,its limited efficacy necessitates more therapeutic strategies,including systemic therapies.The management of ICC involves a multidisciplinary approach,with treatment decisions guided by patient-specific and tumor-specific factors.Gemcitabine-cisplatin(GEMCIS)chemotherapy has been a standard first-line therapy,but recent advancements in immunotherapy,particularly the introduction of durvalumab,have provided new hope.Additionally,gene mutation-based therapies,targeting fibroblast growth factor receptors(FGFRs),isocitrate dehydrogenase-1(IDH1),human epidermal growth factor receptor-2(HER2),and B-RAF proto-oncogene(BRAF),offer promising prospects for personalized treatment.High-throughput genomic profiling technologies have facilitated the identification of actionable targets and the development of innovative therapeutic approaches.This review summarizes the mutation-based therapies in ICC,including FDA-approved targeted drugs and ongoing clinical trials,highlighting the evolving landscape of ICC treatment.
基金
supported by the National Natural Science Foundation of China(No.82173260,No.81972708,No.82072681,No.82003082,No.81773069,No.81830102,No.81772578)
the National Key R&D Program of China(No.2019YFC1315800,2019YFC1315802,2018YFA0109400)
Shanghai Technical Standard Program(21DZ2201100).
